Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28807336
DOI
10.1016/j.anndiagpath.2017.04.007
PII: S1092-9134(17)30088-6
Knihovny.cz E-zdroje
- Klíčová slova
- Fumarate hydratase-deficient renal cell carcinoma, Kidney, PD-1 ligand (PD-L1) receptor, Programmed death-1 (PD-1) receptor,
- MeSH
- antigeny CD274 metabolismus MeSH
- antigeny CD279 metabolismus MeSH
- dospělí MeSH
- fumarasa nedostatek metabolismus MeSH
- imunohistochemie metody MeSH
- karcinom z renálních buněk metabolismus patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory ledvin metabolismus patologie MeSH
- přežití bez známek nemoci MeSH
- tumor infiltrující lymfocyty metabolismus patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antigeny CD274 MeSH
- antigeny CD279 MeSH
- CD274 protein, human MeSH Prohlížeč
- fumarasa MeSH
- PDCD1 protein, human MeSH Prohlížeč
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients. This is the first study to assess the expression of programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) in FH-RCC. Formalin-fixed paraffin-embedded samples from 13 FH-RCCs collected in an international multi-institutional study, were evaluated by immunohistochemistry (IHC) for PD-1/PD-L1 reactivity in tumor cells and tumor infiltrating lymphocytes (TILs). PD-1/PD-L1 expression was further evaluated by qPCR. By IHC, PD-1 was negative in tumor cells in all 13 cases. PD-L1 was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively. In TILs, PD-1 was positive in 1/13, weak positive in 3/13, and negative in 9/13 cases. In TILs, PD-L1 was weak positive by IHC in 5/13, and negative in 8/13 cases, respectively. qPCR confirmed the result for 2 of 3 IHC weak positive PD-1 samples. Of 7 IHC weak positive samples (in tumor cells), PD-L1 mRNA was detected in all 7 tumors. The majority of FH-RCCs did not express PD-1/PD-L1 by IHC, which was confirmed by molecular analysis. PD-1/PD-L1 expression in FH-RCC is restricted to a proportion of cases which may benefit from targeted therapies.
Bart's Cancer Center London United Kingdom
Calgary Laboratory Services University of Calgary Calgary AB Canada
Department of Pathology Bellvitge Biomedical Research Institute Barcelona Spain
Department of Pathology Instituto Nacional de Cancerologia Mexico City Mexico
Department of Pathology Medical College Wisconsin Milwaukee WI USA
Department of Pathology University Erlangen Germany
Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH USA
Citace poskytuje Crossref.org
